Literature DB >> 31111432

Successful treatment of severe perianal Crohn's disease with infliximab in an HIV-positive patient.

Maria Ana Rafael1, Luís Carvalho Lourenço2, Ana Maria Oliveira2, Teresa Branco3, Carla Carneiro4, Ana Costa5, Jorge Reis2.   

Abstract

We present the case of a woman infected with the HIV type 1, controlled with highly active antiretroviral therapy. In the meantime, she developed a severe perianal disease, with complex fistulae and chronic anal fissures. After developing a severe chronic diarrhea, a total ileocolonoscopy with biopsies was performed, showing multiple ileal and segmental colonic erosions. Histology favoured a Crohn's disease diagnosis. Despite the limited experience of anti-tumour necrosis factor agents in the HIV-infected population, infliximab was started in this patient, due to her severe and symptomatic Crohn's disease, with a controlled HIV infection. No side effects were reported and her bowel movements and perianal disease improved right after induction regimen with infliximab. 1 year after starting this therapy she is in clinical and endoscopic remission. The CD4+ T-cell count remained stable, the HIV-RNA undetectable and no opportunistic infections were reported during follow-up period. Data concerning the use of anti-tumour necrosis factor drugs is limited in patients with both inflammatory bowel disease and HIV infection. Only three cases of Crohn's disease and concomitant HIV infection treated with infliximab were reported in the literature. This case report might help future decisions in patients with a similar clinical situation.

Entities:  

Keywords:  Human immunodeficiency virus; Inflammatory bowel disease; Tumour necrosis factor inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31111432     DOI: 10.1007/s12328-019-00992-w

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  10 in total

1.  Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab.

Authors:  Norman B Gaylis
Journal:  J Clin Rheumatol       Date:  2012-04       Impact factor: 3.517

2.  Infliximab therapy for HIV positive Crohn's disease: A case report.

Authors:  Syed F Habib; Muhammad Z Hasan; I Salam
Journal:  J Crohns Colitis       Date:  2009-07-24       Impact factor: 9.071

3.  Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis.

Authors:  Jérôme Filippi; Pierre-Marie Roger; Stéphane M Schneider; Jacques Durant; Jean-Philippe Breittmayer; Sylvia Benzaken; Alain Bernard; Pierre Dellamonica; Xavier Hébuterne
Journal:  Arch Intern Med       Date:  2006-09-18

4.  Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease.

Authors:  B Beltrán; P Nos; G Bastida; M Iborra; M Hoyos; J Ponce
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 5.  Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.

Authors:  Mio Nakamura; Michael Abrouk; Benjamin Farahnik; Tian H Zhu; Tina Bhutani
Journal:  Cutis       Date:  2018-01

6.  Use of infliximab to treat psoriatic arthritis in HIV-positive patients.

Authors:  Jérémie Sellam; Béatrice Bouvard; Charles Masson; Mickael Rousière; Caroline Villoutreix; Karine Lacombe; Vanessa Khanine; Jean-Marie Chennebault; Christian Leclech; Maurice Audran; Francis Berenbaum
Journal:  Joint Bone Spine       Date:  2007-01-31       Impact factor: 4.929

7.  Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia.

Authors:  Hani Almoallim; Ibtisam Jali; Ghassan Wali
Journal:  Joint Bone Spine       Date:  2013-03-01       Impact factor: 4.929

8.  The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.

Authors:  E J Cepeda; F M Williams; M L Ishimori; M H Weisman; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-12-13       Impact factor: 19.103

Review 9.  Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.

Authors:  Stephanie M Gallitano; Laura McDermott; Kanwaljit Brar; Eve Lowenstein
Journal:  J Am Acad Dermatol       Date:  2016-01-14       Impact factor: 11.527

Review 10.  Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.

Authors:  M J Shale; C H Seow; C S Coffin; G G Kaplan; R Panaccione; S Ghosh
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

  10 in total
  1 in total

1.  Biological treatment usage in patients with HIV and rheumatic disease, 2003-2021: long-term safety and follow-up.

Authors:  Benjamin Sornrung Naovarat; Gloria Salazar; Mariko Ishimori; Francis M Williams; John D Reveille
Journal:  RMD Open       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.